Standout Papers

Targeting the PI3K pathway in cancer: are we making ... 2011 2026 2016 2021 768
  1. Targeting the PI3K pathway in cancer: are we making headway? (2018)
    Filip Jankú, Timothy A. Yap et al. Nature Reviews Clinical Oncology
  2. Autophagy as a target for anticancer therapy (2011)
    Filip Jankú, David J. McConkey et al. Nature Reviews Clinical Oncology
  3. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway (2013)
    Jiří Polívka, Filip Jankú Pharmacology & Therapeutics
  4. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer (2015)
    Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology
  5. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study (2018)
    Dejan Juric, Jordi Rodón et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 11 from Science/Nature 64 standout
Sub-graph 1 of 21

Citing Papers

Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline Update
2024 Standout
Palliative Care for Patients With Cancer: ASCO Guideline Update
2024 Standout
1 intermediate paper

Works of Filip Jankú being referenced

Associations between the gut microbiome and fatigue in cancer patients
2021
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early‐phase oncology clinical trials
2016

Author Peers

Author Last Decade Papers Cites
Filip Jankú 5930 6534 4288 427 14.5k
Ivan Bièche 5756 10904 2559 489 19.8k
Sandrine Faivre 6717 6568 3320 284 14.6k
Bryan T. Hennessy 8714 9505 2904 259 19.1k
Katherine L. Nathanson 4751 8189 2288 266 15.7k
Shinzaburo Noguchi 5973 5043 2708 383 13.4k
W. Marston Linehan 4798 8346 5379 292 14.8k
Antonio Russo 5634 4657 2301 368 11.6k
David S. Hong 10195 9319 6145 810 22.5k
Éric Raymond 10556 8626 4391 364 20.8k
Jennifer R. Grandis 9884 10189 4844 341 21.5k

All Works

Loading papers...

Rankless by CCL
2026